X0306 4 2020-06-02 0 0000792977 AMAG PHARMACEUTICALS, INC. AMAG 0001785557 JOHNSON DAVID EDWARD 520 MADISON AVENUE NEW YORK NY 10022 1 0 1 0 Common Stock, par value $0.01 per share ("Common Stock") 2020-06-02 4 A 0 10269 A 14676 D Common Stock 3499428 I See footnote Stock Option (Right to Buy) 8.52 2020-06-02 4 A 0 21289 A 2030-06-02 Common Stock 21289 21289 D Each restricted stock unit represents a contingent right to receive one share of Common Stock of AMAG Pharmaceuticals, Inc. (the "Issuer"). These shares of Common Stock are issuable pursuant to a grant of restricted stock units pursuant to the Issuer's 2019 Equity Incentive Plan (the "Plan") that will vest in twelve equal monthly installments beginning on July 1, 2020; however, delivery of the shares is deferred until the earlier of (a) a Change in Control (as defined in the Issuer's Non-Employee Directors' Deferred Compensation Program) of the Issuer and (b) the date of the director's separation from service to the Issuer. Not applicable. Such securities are held by an affiliated fund and managed account to which Caligan Partners LP ("Caligan") serves as investment manager. David Johnson is the Partner of Caligan and Managing Member of Caligan Partners GP LLC, the general partner of Caligan. Grant of stock option pursuant to the Plan. This option will vest and become exercisable in twelve equal monthly installments commencing July 1, 2020. Remarks: Mr. Johnson disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that Mr. Johnson is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. /s/ David Johnson 2020-06-04